Overview of Intuitive Surgical's Performance#
Stifel has reaffirmed its Buy rating and a price target of $670 for Intuitive Surgical (NASDAQ:ISRG) following the company's impressive first-quarter earnings for 2026. With a market capitalization of $160 billion, Intuitive Surgical is a significant player in the medical device industry. However, some analyses suggest that the stock may be overvalued compared to its Fair Value.
Earnings and Revenue Growth#
In the first quarter, Intuitive Surgical reported a procedure growth of about 16%, surpassing Stifel's estimate of 14% and the consensus estimate of 14.5%. This growth was largely driven by increased utilization in general surgery. The company's revenue also grew by 21% over the past year, indicating effective commercial strategies.
System Revenue and Cost Management#
System revenue saw a notable increase of approximately 25% in the quarter, largely due to the DV5 upgrade cycle. This growth occurred despite challenging market conditions in China and Japan. The company implemented cost-reduction initiatives that improved operating efficiency, with costs of goods sold rising by 18% year-over-year and operating expenses increasing by 10%. Revenue grew by 23% in the first quarter, showcasing strong performance.
Analyst Reactions and Future Projections#
Following the positive earnings report, Stifel raised its financial projections for Intuitive Surgical, citing that the factors boosting the company's performance in 2025 are expected to continue into 2026. Notably, the company reported earnings per share (EPS) of $2.50, exceeding analyst forecasts of $2.12, and revenue of $2.77 billion, surpassing the anticipated $2.62 billion. Despite these strong results, Leerink Partners lowered its price target for Intuitive Surgical to $573 from $622, while maintaining an Outperform rating. Oppenheimer also reiterated a Perform rating, acknowledging that both revenue and GAAP EPS exceeded their estimates and consensus expectations.